Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital
We undertook this survey about the use of clarithromycin in the Ear, Nose, and Throat (ENT) Outpatient Department of Fudan University Hospital to understand its utilization patterns and rational use. A survey of prescriptions given to outpatients was carried out, and detailed information of the patients, including age, sex, diagnosis, combined medication, and other information, was recorded in Excel spreadsheets. The rationale for each prescription was evaluated retrospectively. Based on our analysis, 82.5% of the clarithromycin prescriptions were for the treatment of rhinosinusitis. It was found that the parameters for the diagnosis of this condition were surprisingly broad and should have been more specific. In addition, the clarithromycin dosage regimen varied in clinical practice. For chronic rhinosinusitis, the duration of treatment was between 8 and 16 days, which was not sufficient. Moreover, clarithromycin was prescribed along with considerable numbers of pharmacotherapeutic anti-allergic drugs. Our survey indicated that improvements in the quality of clarithromycin prescriptions in otolaryngology outpatients should be made. Furthermore, the importance of medical education to patients should be emphasized. In addition, the interaction between clarithromycin and other anti-allergic drugs requires further investigation.
KeywordsClarithromycin Drug utilization Prescriptions Otolaryngology outpatients Drug interactions Antibiotics
Compliance with ethical standards
Conflict of interest
We declare that we have no conflicts of interest.
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Ethics Committee of Shanghai Eye, Ear, Nose and Throat Hospital, Shanghai Fudan University, Shanghai, China, approved this study.
- 1.World Health Organization (WHO) (2011) Antimicrobial resistance and its global spread. http://www.who.int/world-health-day/en/index.html. Accessed 27 Sep 2016
- 7.Health Department of China (2007) Prescription administrative policy. http://www.gov.cn/flfg/2007-03/13/content_549406.htm. Accessed 22 Sep 2016
- 8.Harmes KM, Blackwood RA, Burrows HL et al (2013) Otitis media: diagnosis and treatment. Am Fam Phys 88(7):435–440Google Scholar
- 11.Gao YP, Liu HQ, Liu HY et al (2012) Medication compliance analysis of adult chronic rhinosinusitis. J Clin Otorhinolaryngol Head Neck Surg (China) 26(05):224–225Google Scholar
- 14.US Food & Drug Administration (2011) FDA Drug Development and Drug Interactions: Table of Substrates Inhibitors and Inducers. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#4. Accessed 27 Sep 2016